drugset / Trial / NCT00090038

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

NCT00090038

Phase 4 Completed 168 enrolled Biogen
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to provide treatment for patients who have relapsed Non-Hodgkin's lymphoma (NHL) or refractory NHL, and to test the immunity of study subjects after receiving four treatments with rituximab.

Timeline

Start
2003-10
Primary completion
2007-06
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody

Indications